BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci 2013;102:1343-54. [PMID: 23334925 DOI: 10.1002/jps.23450] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Kim M, Laramy JK, Gampa G, Parrish KE, Brundage R, Sarkaria JN, Elmquist WF. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. Drug Metab Dispos 2019;47:1403-14. [PMID: 31619389 DOI: 10.1124/dmd.119.088716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sawicki E, Hillebrand MJ, Rosing H, Schellens JHM, Nuijen B, Beijnen JH. Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar. J Pharm Anal 2016;6:268-75. [PMID: 29403992 DOI: 10.1016/j.jpha.2016.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 You X, Xing Q, Tuo J, Song W, Zeng Y, Hu H. Optimizing surfactant content to improve oral bioavailability of ibuprofen in microemulsions: Just enough or more than enough? International Journal of Pharmaceutics 2014;471:276-84. [DOI: 10.1016/j.ijpharm.2014.05.031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
4 Rojekar S, Fotooh Abadi L, Pai R, Mahajan K, Kulkarni S, Vavia PR. Multi-organ targeting of HIV-1 viral reservoirs with etravirine loaded nanostructured lipid carrier: An in-vivo proof of concept. Eur J Pharm Sci 2021;164:105916. [PMID: 34166780 DOI: 10.1016/j.ejps.2021.105916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Haase K, Offeddu GS, Gillrie MR, Kamm RD. Endothelial Regulation of Drug Transport in a 3D Vascularized Tumor Model. Adv Funct Mater 2020;30:2002444. [PMID: 33692661 DOI: 10.1002/adfm.202002444] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 16.5] [Reference Citation Analysis]
6 Kaur V, Garg T, Rath G, Goyal AK. Therapeutic potential of nanocarrier for overcoming to P-glycoprotein. J Drug Target 2014;22:859-70. [PMID: 25101945 DOI: 10.3109/1061186X.2014.947295] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 2.1] [Reference Citation Analysis]
7 Matzneller P, Kussmann M, Eberl S, Maier-Salamon A, Jäger W, Bauer M, Langer O, Zeitlinger M, Poeppl W. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Eur J Drug Metab Pharmacokinet 2018;43:599-606. [PMID: 29616423 DOI: 10.1007/s13318-018-0474-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
8 Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Deliv Transl Res 2017;7:125-31. [PMID: 27864786 DOI: 10.1007/s13346-016-0346-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Hedaya MA, Thomas V, Abdel-Hamid ME, Kehinde EO, Phillips OA. Comparative Pharmacokinetic Study for Linezolid and Two Novel Antibacterial Oxazolidinone Derivatives in Rabbits: Can Differences in the Pharmacokinetic Properties Explain the Discrepancies between Their In Vivo and In Vitro Antibacterial Activities? Pharmaceutics 2017;9:E34. [PMID: 28880210 DOI: 10.3390/pharmaceutics9030034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Rowbottom C, Pietrasiewicz A, Tuczewycz T, Grater R, Qiu D, Kapadnis S, Trapa P. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats. Pharmacol Res Perspect 2021;9:e00740. [PMID: 33660938 DOI: 10.1002/prp2.740] [Reference Citation Analysis]
11 Liu Y, Wang L, Zhao Y, He M, Zhang X, Niu M, Feng N. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. International Journal of Pharmaceutics 2014;476:169-77. [DOI: 10.1016/j.ijpharm.2014.09.052] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
12 Yuan Y, Che X, Zhao M, Wang Y, Liu Y, Schwendeman A, Li S. Development of cyclosporine A microemulsion for parenteral delivery. J Microencapsul 2015;32:273-80. [PMID: 25761521 DOI: 10.3109/02652048.2015.1010461] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Smolinski MP, Urgaonkar S, Pitzonka L, Cutler M, Lee G, Suh KH, Lau JYN. Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. J Med Chem 2021;64:3677-93. [PMID: 33729781 DOI: 10.1021/acs.jmedchem.0c01826] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 2014;134:1484-94. [PMID: 24037730 DOI: 10.1002/ijc.28475] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 11.3] [Reference Citation Analysis]
15 Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther 2015;355:264-71. [PMID: 26354993 DOI: 10.1124/jpet.115.228213] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
16 Saneja A, Khare V, Alam N, Dubey RD, Gupta PN. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opinion on Drug Delivery 2013;11:121-38. [DOI: 10.1517/17425247.2014.865014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
17 Zhang H, Xu B, Zhang H. Mesoscopic simulation on the microemulsion system stabilized by bola surfactant. Journal of Dispersion Science and Technology. [DOI: 10.1080/01932691.2020.1869033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Jani M, Ambrus C, Magnan R, Jakab KT, Beéry E, Zolnerciks JK, Krajcsi P. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Arch Toxicol 2014;88:1205-48. [DOI: 10.1007/s00204-014-1224-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
19 Zhang H, Zhu Z, Wu Z, Wang F, Xu B, Wang S, Zhang L. Investigation on the formation and stability of microemulsions with Gemini surfactants: DPD simulation. Journal of Dispersion Science and Technology. [DOI: 10.1080/01932691.2021.1961588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li Q, Wang X, Shen A, Zhang Y, Chen Y, Sferra TJ, Lin J, Peng J. Hedyotis diffusa Willd overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells by downregulating the expression of P-glycoprotein and ATP-binding casette subfamily G member 2. Exp Ther Med 2015;10:1845-50. [PMID: 26640560 DOI: 10.3892/etm.2015.2762] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
21 Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model. Mol Cancer Ther 2016;15:819-29. [PMID: 26883271 DOI: 10.1158/1535-7163.MCT-15-0093] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
22 Sapra B, Thatai P, Bhandari S, Sood J, Jindal M, Tiwary A. A critical appraisal of microemulsions for drug delivery: part I. Therapeutic Delivery 2013;4:1547-64. [DOI: 10.4155/tde.13.116] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet 2017;56:825-92. [PMID: 28210973 DOI: 10.1007/s40262-017-0506-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 21.0] [Reference Citation Analysis]
24 Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. European Journal of Pharmacology 2015;746:258-66. [DOI: 10.1016/j.ejphar.2014.11.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
25 Sadhukha T, Layek B, Prabha S. Incorporation of lipolysis in monolayer permeability studies of lipid-based oral drug delivery systems. Drug Deliv and Transl Res 2018;8:375-86. [DOI: 10.1007/s13346-017-0383-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
26 Song JM, Kirtane AR, Upadhyaya P, Qian X, Balbo S, Teferi F, Panyam J, Kassie F. Intranasal delivery of liposomal indole-3-carbinol improves its pulmonary bioavailability. Int J Pharm 2014;477:96-101. [PMID: 25311179 DOI: 10.1016/j.ijpharm.2014.10.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
27 Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? Pharm Res 2019;37:12. [PMID: 31873819 DOI: 10.1007/s11095-019-2745-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
28 van Tellingen O, Yetkin-arik B, de Gooijer M, Wesseling P, Wurdinger T, de Vries H. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates 2015;19:1-12. [DOI: 10.1016/j.drup.2015.02.002] [Cited by in Crossref: 422] [Cited by in F6Publishing: 373] [Article Influence: 60.3] [Reference Citation Analysis]
29 Ahmed OA, Badr-eldin SM, Tawfik MK, Ahmed TA, El-say KM, Badr JM. Design and Optimization of Self-Nanoemulsifying Delivery System to Enhance Quercetin Hepatoprotective Activity in Paracetamol-Induced Hepatotoxicity. Journal of Pharmaceutical Sciences 2014;103:602-12. [DOI: 10.1002/jps.23834] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
30 Natarajan K, Baer MR, Ross DD. Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance. In: Efferth T, editor. Resistance to Targeted ABC Transporters in Cancer. Cham: Springer International Publishing; 2015. pp. 53-88. [DOI: 10.1007/978-3-319-09801-2_3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies. Drug Dev Ind Pharm 2017;43:584-94. [PMID: 28010129 DOI: 10.1080/03639045.2016.1274901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
32 Guo Y, Mao X, Zhang J, Sun P, Wang H, Zhang Y, Ma Y, Xu S, Lv R, Liu X. Oral delivery of lycopene-loaded microemulsion for brain-targeting: preparation, characterization, pharmacokinetic evaluation and tissue distribution. Drug Deliv 2019;26:1191-205. [PMID: 31738085 DOI: 10.1080/10717544.2019.1689312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
33 Goutal S, Langer O, Auvity S, Andrieux K, Coulon C, Caillé F, Gervais P, Cisternino S, Declèves X, Tournier N. Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. Drug Deliv Transl Res 2018;8:536-42. [PMID: 29294257 DOI: 10.1007/s13346-017-0472-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N. Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET. J Nucl Med 2018;59:973-9. [PMID: 29175983 DOI: 10.2967/jnumed.117.195800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
35 Subongkot T, Ngawhirunpat T. Development of a novel microemulsion for oral absorption enhancement of all-trans retinoic acid. Int J Nanomedicine 2017;12:5585-99. [PMID: 28831254 DOI: 10.2147/IJN.S142503] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
36 Gampa G, Kenchappa RS, Mohammad AS, Parrish KE, Kim M, Crish JF, Luu A, West R, Hinojosa AQ, Sarkaria JN, Rosenfeld SS, Elmquist WF. Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma. Sci Rep 2020;10:6524. [PMID: 32300151 DOI: 10.1038/s41598-020-63494-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]